Novo Nordisk to open $100M plant in NC, USA

Danish diabetes giant Novo Nordisk says it will open a $100.0 million, 200,000-square-foot expanded facility in Clayton, North Carolina, to meet the USA's increasing demand for its FlexPen, the world's number one selling popular prefilled insulin pen.

The event marks the second expansion in three years of the company's only insulin manufacturing facility in the USA, doubling its domestic insulin filling capabilities and initiating the first domestic production of FlexPen. As a result, more than 50 jobs have been created. To date, Novo Nordisk has expanded its workforce in Clayton to 400.

Approximately 54 million Americans have pre-diabetes, a condition that puts them at increased risk for diabetes, a chronic disease affecting nearly 21 million US citizens. Many people with diabetes take insulin to control their blood sugar. Insulin pens can be used instead of vials and syringes for giving insulin injections. FlexPen is exclusively available for use with the Novo Nordisk insulin analog product portfolio.